Cargando…

Traumatic Tonsillar Hemorrhage during Hemophilia A Treatment with Emicizumab

Reports on the treatment of bleeding associated with emicizumab administration are scarce. Herein, we report the case of an eight-year-old boy with moderate hemophilia A with an inhibitor who experienced tonsillar hemorrhage while undergoing emicizumab treatment. He visited our hospital for postpran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Fumiya, Terada, Kazuki, Furudate, Kazuki, Noguchi, Yasushi, Igarashi, Shunji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036207/ https://www.ncbi.nlm.nih.gov/pubmed/35466180 http://dx.doi.org/10.3390/hematolrep14020016

Ejemplares similares

Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage
por: Yamada, Yuya, et al.
Publicado: (2022)

Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)

Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia
por: Matsumoto, Megumi, et al.
Publicado: (2022)

Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
por: Albattat, Sami, et al.
Publicado: (2023)

Spontaneus tonsillar hemorrhage
por: Milhomem Rocha, Savya Cybelle, et al.
Publicado: (2015)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Traumatic Transient Herniation Concomitant with Tonsillar Hemorrhagic Contusion in a Child
por: Öğrenci, Ahmet, et al.
Publicado: (2017)

Spontaneous Tonsillar Hemorrhage and Post-Tonsillectomy Hemorrhage
por: Kim, Yeon Soo, et al.
Publicado: (2010)

Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021)

P1616: EMICIZUMAB FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A
por: Sridharan, Meera, et al.
Publicado: (2023)

Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report
por: Al-Banaa, Kadhim, et al.
Publicado: (2019)

Non-inhibitory antibodies inducing increased emicizumab clearance in a severe hemophilia A inhibitor patient
por: Harroche, Annie, et al.
Publicado: (2021)

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

Management of children with hemophilia A on emicizumab who need surgery
por: Belletrutti, Mark, et al.
Publicado: (2023)

Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
por: Kizilocak, Hande, et al.
Publicado: (2019)

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
por: Gelbenegger, Georg, et al.
Publicado: (2020)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
por: Yada, Koji, et al.
Publicado: (2019)

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
por: Le Quellec, Sandra
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW
por: Al-Housni, Zainab, et al.
Publicado: (2023)

Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
por: Zhou, Zheng-Yi, et al.
Publicado: (2020)

Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention
por: Dane, Kathryn E., et al.
Publicado: (2019)

Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature
por: Kizilocak, Hande, et al.
Publicado: (2023)

Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A
por: Kaneda, Makoto, et al.
Publicado: (2021)

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)

Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report
por: Guillaume, Louise, et al.
Publicado: (2021)

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report
por: Warren, Beth Boulden, et al.
Publicado: (2021)

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
por: Matsumoto, Naoki, et al.
Publicado: (2023)

Repeated Diffuse Alveolar Hemorrhage in a Patient with Hemophilia B
por: Kasai, Hajime, et al.
Publicado: (2017)

Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A
por: Iarossi, Michael, et al.
Publicado: (2022)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
por: Yang, Renchi, et al.
Publicado: (2022)

Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study
por: Donners, Anouk A. M. T., et al.
Publicado: (2022)

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023)

Coagulation assessment with thromboelastography during abdominal endovascular aneurysm repair in a patient with hemophilia A
por: Sato, Kazuki, et al.
Publicado: (2020)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_87u1lfqj8etditf7t5n91ctss0